INIsabelle Nel

Isabelle Nel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Isabelle Nel has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Similarities and singularities between innate-like T cell subsets in adults with type 1 diabetes

    by Isabelle Nel, Gaëlle Vermillac, Léo Bertrand, Lucie Beaudoin, Etienne Larger, Ioannis Theodorou, Agnès Lehuen

  • Identification of the Novel HLA‐A*02:1269 Allele by Next‐Generation Sequencing

    by Noémie Blumenthal, Karine Bruniquet, Béatrice Pédron, Isabelle Nel

    The novel allele HLA‐A*02:1269 differs from HLA‐A*02:01:01:01 by one nucleotide substitution in codon 184 in exon 4.


  • Les cellules MAIT dans le diabète de type 1 chez l'homme

    by Isabelle Nel

    Le diabète de type 1 (DT1) est une maladie auto-immune caractérisée par l'implication du système immunitaire adaptatif mais également inné. Des altérations de l'homéostasie intestinale sont également décrites. Les cellules MAIT appartiennent à la famille des lymphocytes T non conventionnels et présentent la particularité de reconnaître par la molécule MR1 des ligands principalement d'origine bactérienne. Il est reconnu que les lymphocytes MAIT interagissent fortement avec le microbiote intestinal. Le DT1 est l'une des plus fréquentes maladies de l'enfance. Cependant, le DT1 est diagnostiqué aussi bien chez l'enfant que chez l'adulte. Pour déterminer si les cellules MAIT pourraient être impliquées dans la physiopathologie du DT1, la fréquence, le phénotype et la fonction des cellules MAIT ont été analysés par cytométrie en flux dans le sang d'enfants et d'adultes DT1. La fréquence des cellules MAIT chez les enfants DT1 au moment du diagnostic de leur diabète est diminuée. Ce résultat pourrait être la conséquence de la migration des cellules MAIT du sang vers les tissus inflammés ou/et de leur activation prolongée entraînant leur exhaustion. Il est intéressant de noter que, chez les adultes, les altérations des cellules MAIT sont plus importantes après plusieurs années de DT1 qu'au moment du diagnostic. Ces résultats corroborent l'idée d'une hétérogénéité entre les patients DT1 en fonction de leur âge, impliquant probablement des mécanismes physiopathologiques différents. Tous ces résultats nous amènent à penser que, en accord avec ce qui a été montré chez la souris NOD, les cellules MAIT pourraient jouer un rôle dans la physiopathologie du DT1. De plus, des altérations des cellules MAIT sont observées chez les patients avant l'apparition des signes cliniques du DT1 suggérant que les cellules MAIT puissent devenir un nouveau biomarqueur prédictif du risque de développer un DT1. D'autre part, les altérations des cellules MAIT sont plus importantes chez les adultes que chez les enfants diagnostiqués diabétiques depuis plusieurs années. Ceci nous laisse imaginer que les cellules MAIT pourraient également être impliquées dans les étapes insidieuses qui amènent au développement de complications chez les adultes DT1. Des études approfondies de ces différentes hypothèses sont nécessaires, cependant il apparaît clairement que les cellules MAIT puissent devenir un nouvel outil d'intervention thérapeutique dans les décennies à venir.

  • IgG-immunoadsorptions and eculizumab combination in STEC-hemolytic and uremic syndrome pediatric patients with neurological involvement

    by Charlotte Duneton, Theresa Kwon, Claire Dossier, Veronique Baudouin, Marc Fila, Patricia Mariani-Kurkdijan, Isabelle Nel, Olivia Boyer, Julien Hogan

    Background Neurological complications pose a significant threat in pediatric hemolytic and uremic syndrome (HUS) resulting from infections with Shiga toxin-producing Escherichia coli (STEC), with no established treatment. The involvement of complement activation in the pathogenesis of STEC-HUS is acknowledged, and eculizumab (ECZ), a terminal complement blocker, has been documented in several pediatric series with inconsistent results. Antibody-mediated mechanisms have also been suggested, with IgG-immunoadsorption (IgIA) showing promise in adults with neurological complications. We aimed to assess the benefit of combining IgIA with ECZ in pediatric patients with neurological STEC-HUS compared to patients treated with ECZ alone or supportive care. Methods Multicenter retrospective study conducted on pediatric patients (< 18 years) with neurological STEC-HUS treated with IgIA + ECZ or ECZ alone from 2010 to 2020 in France. A historical cohort treated with supportive care served as controls. Primary outcome included survival and neurological evaluation at 1-year follow-up (dichotomized as normal vs. abnormal). Results A total of 42 children were included: 18 treated with IgIA + ECZ, 24 with ECZ alone, and 27 with supportive care. Although there was no significant difference in survival between groups, three deaths occurred in the control group in the acute phase, while none was reported in both the IgIA + ECZ and ECZ alone groups, despite presenting with more severe neurological symptoms for IgIA + ECZ patients. No significant association was found between treatment group and 1-year neurological evaluation after adjustment for age, sex, and initial neurological presentation. Conclusions Systematic association of IgIA + ECZ is not supported for all neurological STEC-HUS pediatric patients; potential rescue therapy for severe cases warrants consideration. Graphical Abstract A higher resolution version of the Graphical abstract is available as Supplementary information


  • Open Access

    MAIT cell alterations in adults with recent-onset and long-term type 1 diabetes

    by Isabelle Nel, Lucie Beaudoin, Zouriatou Gouda, Camille Rousseau, Pauline Soulard, Matthieu Rouland, Léo Bertrand, Christian Boitard, Etienne Larger, Agnès Lehuen

    Aims/hypothesis Mucosal-associated invariant T (MAIT) cells are innate-like T lymphocytes expressing an αβ T cell antigen receptor that recognises the MHC-related 1 molecule. MAIT cells are altered in children at risk for and with type 1 diabetes, and mouse model studies have shown MAIT cell involvement in type 1 diabetes development. Since several studies support heterogeneity in type 1 diabetes physiopathology according to the age of individuals, we investigated whether MAIT cells were altered in adults with type 1 diabetes. Methods MAIT cell frequency, phenotype and function were analysed by flow cytometry, using fresh peripheral blood from 21 adults with recent-onset type 1 diabetes (2–14 days after disease onset) and 47 adults with long-term disease (>2 years after diagnosis) compared with 55 healthy blood donors. We also separately analysed 17 women with long-term type 1 diabetes and an associated autoimmune disease, compared with 30 healthy women and 27 women with long-term type 1 diabetes. Results MAIT cells from adults with recent-onset type 1 diabetes, compared with healthy adult donors, harboured a strongly activated phenotype indicated by an elevated CD25+ MAIT cell frequency. In adults with long-term type 1 diabetes, MAIT cells displayed an activated and exhausted phenotype characterised by high CD25 and programmed cell death 1 (PD1) expression and a decreased production of proinflammatory cytokines, IL-2, IFN-γ and TNF-α. Even though MAIT cells from these patients showed upregulated IL-17 and IL-4 production, the polyfunctionality of MAIT cells was decreased (median 4.8 vs 13.14% of MAIT cells, p < 0.001) and the frequency of MAIT cells producing none of the effector molecules analysed increased (median 34.40 vs 19.30% of MAIT cells, p < 0.01). Several MAIT cell variables correlated with HbA1c level and more particularly in patients with recent-onset type 1 diabetes. In women with long-term type 1 diabetes, MAIT cell alterations were more pronounced in those with an associated autoimmune disease than in those without another autoimmune disease. In women with long-term type 1 diabetes and an associated autoimmune disease, there was an increase in CD69 expression and a decrease in the survival B-cell lymphoma 2 (BCL-2) (p < 0.05) and CD127 (IL-7R) (p < 0.01) marker expression compared with women without a concomitant autoimmune disorder. Concerning effector molecules, TNF-α and granzyme B production by MAIT cells was decreased. Conclusions/interpretation Alterations in MAIT cell frequency, phenotype and function were more pronounced in adults with long-term type 1 diabetes compared with adults with recent-onset type 1 diabetes. There were several correlations between MAIT cell variables and clinical characteristics. Moreover, the presence of another autoimmune disease in women with long-term type 1 diabetes further exacerbated MAIT cell alterations. Our results suggest that MAIT cell alterations in adults with type 1 diabetes could be associated with two aspects of the disease: impaired glucose homeostasis; and autoimmunity. Graphical abstract